



CANCER **PROGRESS** *by Defined Health*

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth
unconventional insight



Symphogen: Focusing on mAb Mixtures / Cancer

- Privately held company - 100 employees
 - Headquarters in Ballerup, DK
 - Clinical Development in NJ, US
- Next-generation mAb therapeutics
 - Mixtures against single & multi-targets
- Sym004 Anti-EGFR mAb Opportunity
 - Novel MoAs vs. single EGFR mAbs
 - On-going trials in mCRC, ESCC & GBM
 - Potential for accelerated approval
- Value Creating Collaborations
 - Genentech Ph1 infectious disease program
 - Baxalta immuno-oncology collaboration



Strong Investor Base

NOVO

EssexWoodlands



Sunstone
Capital




Danica Pension

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth
unconventional insight



Innovative Oncology Pipeline of mAbs & mAb Mixtures



Examples of Strategic Challenges / Opportunities

- Antibody platform with applications across many therapeutic areas
 - Options: collaboration to maximize shots on goal? focus on self-development?
- How to develop 2nd generation anti-EGFR mAb in a well established market with entrenched competitors in rapidly evolving indications
 - Options: collaborate to allow conduct of large trials in early lines of treatment? self-develop niche market for rapid market entry?

Examples of Strategic Challenges / Opportunities

- How to handle a returned asset (anti-EGFR mAb) in mid-clinical development?
 - Options: Panic? Re-partner? Restructure organization/refinance to allow self-development?
- As a small biotech how to take advantage of the incredibly promising, but overwhelmingly competitive I-O opportunities?
 - Options: Partner early? Self-develop to value inflection point?